CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations

Oncotarget

Volumn 6, Issue 23, 2015, Pages 19661-19670

  Khanna, Anchit ^a,b   Rane, Jayant K ^c   Kivinummi, Kati K ^a   Urbanucci, Alfonso ^a,d   Helenius, Merja A ^a   Tolonen, Teemu T ^a   Saramäki, Outi R ^a   Latonen, Leena ^a   Manni, Visa ^a   Pimanda, John E ^b   Maitland, Norman J ^c   Westermarck, Jukka ^e   Visakorpi, Tapio ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF YORK   (United Kingdom)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF TURKU   (Finland)

Author keywords

Androgen receptor; Cancer stem like cells; Castration resistant prostate cancer; CIP2A

Indexed keywords

ANDROGEN RECEPTOR; CANCEROUS INHIBITOR OF PROTEIN PHOSPHATASE 2A; ENZYME INHIBITOR; MESSENGER RNA; UNCLASSIFIED DRUG; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AR PROTEIN, HUMAN; AUTOANTIGEN; KIAA1524 PROTEIN, HUMAN; MEMBRANE PROTEIN; PROTEIN BINDING;

ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER STEM CELL; CANCEROUS INHIBITOR OF PROTEIN PHOSPHATASE 2A GENE; CELL POPULATION; CELL VIABILITY; CLINICAL ARTICLE; COLONY FORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LNCAP CELL LINE; MALE; MOLECULAR PATHOLOGY; PROSTATE CANCER; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; BINDING SITE; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; INTRON; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RNA INTERFERENCE; TIME FACTOR; TUMOR CELL CULTURE; TUMOR CELL LINE; UPREGULATION;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; AUTOANTIGENS; BINDING SITES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; HUMANS; INTRONS; MALE; MEMBRANE PROTEINS; MOLECULAR TARGETED THERAPY; NEOPLASTIC STEM CELLS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN BINDING; RECEPTORS, ANDROGEN; RNA INTERFERENCE; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 84939224156     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3875     Document Type: Article

References (26)

1. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J and Kallioniemi OP. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature genetics. 1995; 9:401-406.
2. Waltering KK, Urbanucci A and Visakorpi T. Androgen receptor (AR) aberrations in castration-resistant prostate cancer. Molecular and cellular endocrinology. 2012; 360:38-43.
3. Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M and Miyamoto M. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer research. 2003; 63:149-153.
4. Visakorpi T. Novel endocrine aspects of prostate cancer. Molecular and cellular endocrinology. 2012; 360:1-2.
5. Rane JK, Pellacani D and Maitland NJ. Advanced prostate cancer--a case for adjuvant differentiation therapy. Nature reviews Urology. 2012; 9:595-602.
6. Maitland NJ and Collins AT. Prostate cancer stem cells: a new target for therapy. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2008; 26:2862-2870.
7. Oldridge EE, Pellacani D, Collins AT and Maitland NJ. Prostate cancer stem cells: are they androgen-responsive? Molecular and cellular endocrinology. 2012; 360:14-24.
8. Qin J, Liu X, Laffin B, Chen X, Choy G, Jeter CR, Calhoun-Davis T, Li H, Palapattu GS, Pang S, Lin K, Huang J, Ivanov I, Li W, Suraneni MV and Tang DG. The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration. Cell stem cell. 2012; 10:556-569.
9. Khanna A. Regulation of Cancerous inhibitor of PP2A (CIP2A) by small molecule inhibitor for c-Jun NH 2-Terminal Kinases (JNKs), SP600125, in Human Fibrosarcoma (HT1080) cells. F1000Research. 2013; 2.
10. Khanna A, Bockelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M, Junnila S, Murphy DJ, Evan GI, Haglund C, Westermarck J and Ristimaki A. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst. 2009; 101:793-805.
11. Khanna A, Kauko O, Bockelman C, Laine A, Schreck I, Partanen JI, Szwajda A, Bormann S, Bilgen T, Helenius M, Pokharel YR, Pimanda J, Russel MR, Haglund C, Cole KA, Klefstrom J, et al. Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells. Cancer Res. 2013; 73:6757-6769.
12. Khanna A, Okkeri J, Bilgen T, Tiirikka T, Vihinen M, Visakorpi T and Westermarck J. ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells. PLoS One. 2011; 6:e17979.
13. Khanna A, Pimanda JE and Westermarck J. Cancerous Inhibitor of Protein Phosphatase 2A, an Emerging Human Oncoprotein and a Potential Cancer Therapy Target. Cancer research. 2013.
14. Junttila MR, Puustinen P, Niemela M, Ahola R, Arnold H, Bottzauw T, Ala-aho R, Nielsen C, Ivaska J, Taya Y, Lu SL, Lin S, Chan EK, Wang XJ, Grenman R, Kast J, et al. CIP2A inhibits PP2A in human malignancies. Cell. 2007; 130:51-62.
15. Puustinen P, Rytter A, Mortensen M, Kohonen P, Moreira JM and Jaattela M. CIP2A oncoprotein controls cell growth and autophagy through mTORC1 activation. J Cell Biol. 2014; 204:713-727.
16. Vaarala MH, Vaisanen MR and Ristimaki A. CIP2A expression is increased in prostate cancer. J Exp Clin Cancer Res. 2010; 29:136.
17. Kroon P, Berry PA, Stower MJ, Rodrigues G, Mann VM, Simms M, Bhasin D, Chettiar S, Li C, Li PK, Maitland NJ and Collins AT. JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stemlike cells. Cancer Res. 2013; 73:5288-5298.
18. Leinonen KA, Saramaki OR, Furusato B, Kimura T, Takahashi H, Egawa S, Suzuki H, Keiger K, Ho Hahm S, Isaacs WB, Tolonen TT, Stenman UH, Tammela TL, Nykter M, Bova GS and Visakorpi T. Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer. Cancer Epidemiol Biomarkers Prev. 2013; 22:2333-2344.
19. Waltering KK, Helenius MA, Sahu B, Manni V, Linja MJ, Janne OA and Visakorpi T. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer research. 2009; 69:8141-8149.
20. Bhardwaj A, Singh S, Srivastava SK, Arora S, Hyde SJ, Andrews J, Grizzle WE and Singh AP. Restoration of PPP2CA expression reverses epithelial-to-mesenchymal transition and suppresses prostate tumour growth and metastasis in an orthotopic mouse model. British journal of cancer. 2014; 110:2000-2010.
21. Bluemn EG, Spencer ES, Mecham B, Gordon RR, Coleman I, Lewinshtein D, Mostaghel E, Zhang X, Annis J, Grandori C, Porter C and Nelson PS. PPP2R2C loss promotes castration-resistance and is associated with increased prostate cancer-specific mortality. Molecular cancer research: MCR. 2013; 11:568-578.
22. Pandey P, Seshacharyulu P, Das S, Rachagani S, Ponnusamy MP, Yan Y, Johansson SL, Datta K, Fong Lin M and Batra SK. Impaired expression of protein phosphatase 2A subunits enhances metastatic potential of human prostate cancer cells through activation of AKT pathway. British journal of cancer. 2013; 108:2590-2600.
23. Khanna A and Pimanda JE. Clinical significance of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) in human cancers. International journal of cancer. 2015. Jan 13. doi: 10.1002/ijc.29431. [Epub ahead of print]
24. Collins AT, Berry PA, Hyde C, Stower MJ and Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer research. 2005; 65:10946-10951.
25. Urbanucci A, Sahu B, Seppala J, Larjo A, Latonen LM, Waltering KK, Tammela TL, Vessella RL, Lahdesmaki H, Janne OA and Visakorpi T. Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer. Oncogene. 2012; 31:2153-2163.
26. Khanna A, Patil R and Deshmukh A. Assessment of the potential of pathological stains in human prostate cancer. J Clin Diagn Res. 2014; 8:124-128.